Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.

Abstract:

BACKGROUND:BRCA1 and BRCA2 mutations are found in a proportion of families with multiple early-onset breast cancers. There are a large number of different deleterious mutations in both genes, none of which would be detectable using standard genetic association studies. Single common variants and haplotypes of common variants may capture groups of deleterious mutations since some low prevalence haplotypes of common variants occur more frequently among chromosomes that carry rare, deleterious mutations than chromosomes that do not. METHODS:DNA sequence data for BRCA1 and BRCA2 was obtained from 571 participants from the Australian Breast Cancer Family Study. Genetic variants were classified as either deleterious mutations or common genetic variants. Variants tagging common polymorphisms were selected and haplotypes resolved using Haploview. Their frequency was compared to those with and without deleterious mutations using a permutation test. RESULTS:A common genetic variant in BRCA1 (3232A > G) was found to be over-represented in deleterious mutation carriers (p = 0.05), whereas a common genetic variant in BRCA2 (1342A > C) occurred less frequently in deleterious mutation carriers (p = 0.04). All four of the common BRCA1 variants used to form haplotypes occurred more frequently in the deleterious mutation carriers when compared to the non-carriers, but there was no evidence of a difference in the distributions between the two groups (p = 0.34). In BRCA2, all four common variants were found to occur less frequently in the deleterious mutation carriers when compared to non-carriers, but the evidence for difference in the distribution between the two groups was weak (p = 0.16). Several less common haplotypes of common BRCA1 variants were found to be over-represented among deleterious mutation carriers but there was no evidence for this at the population level. In BRCA2, only the most common haplotype was found to occur more frequently in deleterious mutation carriers, with again no evidence at the population level. CONCLUSIONS:We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using pooled data.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Turkovic L,Gurrin LC,Bahlo M,Dite GS,Southey MC,Hopper JL

doi

10.1186/1471-2407-10-466

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

466

issn

1471-2407

pii

1471-2407-10-466

journal_volume

10

pub_type

杂志文章
  • Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity.

    abstract:BACKGROUND:There is a large body of evidence which suggests that bile acids increase the risk of colon cancer and act as tumor promoters, however, the mechanism(s) of bile acids mediated tumorigenesis is not clear. Previously we showed that deoxycholic acid (DCA), a tumorogenic bile acid, and ursodeoxycholic acid (UDCA...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-219

    authors: Powell AA,Akare S,Qi W,Herzer P,Jean-Louis S,Feldman RA,Martinez JD

    更新日期:2006-09-01 00:00:00

  • The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.

    abstract:BACKGROUND:Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR. The difficulties in obtaining biopsies at progression make it challenging to investigate the appeara...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4108-0

    authors: Demuth C,Madsen AT,Weber B,Wu L,Meldgaard P,Sorensen BS

    更新日期:2018-02-15 00:00:00

  • Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.

    abstract:BACKGROUND:Clinical trials where cancer patients were treated with protease inhibitors have suggested that the serine protease, prostasin, may act as a tumour suppressor. Prostasin is proteolytically activated by the serine protease, matriptase, which has a very high oncogenic potential. Prostasin is inhibited by prote...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-201

    authors: Selzer-Plon J,Bornholdt J,Friis S,Bisgaard HC,Lothe IM,Tveit KM,Kure EH,Vogel U,Vogel LK

    更新日期:2009-06-25 00:00:00

  • Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.

    abstract:BACKGROUND:Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa) patients receiving hormonal therapy. The objective of this study was to determine the prognostic ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2363-5

    authors: Wang Y,Xu F,Pan J,Zhu Y,Shao X,Sha J,Wang Z,Cai Y,Liu Q,Dong B,Xue W,Huang Y

    更新日期:2016-05-24 00:00:00

  • The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma.

    abstract:BACKGROUND:Gambogic acid (GA) is a major active ingredient of gamboge, a widely used traditional Chinese medicine that has been reported to be a potent cytotoxic agent against some malignant tumors. Many studies have shown that the NF-kappa B signaling pathway plays an important role in anti-apoptosis and the drug resi...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-343

    authors: He D,Xu Q,Yan M,Zhang P,Zhou X,Zhang Z,Duan W,Zhong L,Ye D,Chen W

    更新日期:2009-09-25 00:00:00

  • Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.

    abstract:BACKGROUND:Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets. METHODS:Paraffin embedd...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-5-25

    authors: Karavasilis V,Malamou-Mitsi V,Briasoulis E,Tsanou E,Kitsou E,Kalofonos H,Fountzilas G,Fotsis T,Pavlidis N

    更新日期:2005-03-03 00:00:00

  • CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.

    abstract:BACKGROUND:Cytokines are involved in cancer invasion and metastasis. Circulating tumor cells (CTCs) play key role in tumor dissemination and are an independent survival predictor in breast cancer patients. The aim of this study was to assess correlation between CTCs and plasma cytokines in primary breast cancer (PBC) p...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2143-2

    authors: Mego M,Cholujova D,Minarik G,Sedlackova T,Gronesova P,Karaba M,Benca J,Cingelova S,Cierna Z,Manasova D,Pindak D,Sufliarsky J,Cristofanilli M,Reuben JM,Mardiak J

    更新日期:2016-02-19 00:00:00

  • Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?

    abstract:BACKGROUND:The lymphocytes played an important role in the natural history of cancer. The aim of this study was to explore the prognostic value of lymphocyte count and percentage for survival in advanced cancer patients receiving palliative care. METHODS:A retrospective review of clinicopathological data from 378 cons...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3498-8

    authors: Zhao W,Wang P,Jia H,Chen M,Gu X,Liu M,Zhang Z,Cheng W,Wu Z

    更新日期:2017-08-02 00:00:00

  • EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.

    abstract:BACKGROUND:Non-small cell lung cancer (NSCLC) is one of the most aggressive types of cancer. However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistanc...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2527-3

    authors: Gao J,Meng Q,Zhao Y,Chen X,Cai L

    更新日期:2016-07-13 00:00:00

  • Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

    abstract:BACKGROUND:Tamoxifen has dramatically reduced the recurrence and mortality rate of estrogen receptor positive breast cancer. However, the efficacy of tamoxifen varies between individuals and 40% of patients will have a recurrence despite adjuvant tamoxifen treatment. Factors that predict tamoxifen efficacy would be hel...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-612

    authors: Jager NG,Koornstra RH,Vincent AD,van Schaik RH,Huitema AD,Korse TM,Schellens JH,Linn SC,Beijnen JH

    更新日期:2013-12-28 00:00:00

  • Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.

    abstract:BACKGROUND:Many advanced human tumors, including hepatocellular carcinomas (HCC) are auxotrophic for arginine due to down-regulation of argininosuccinate synthetase (ASS1), the rate-limiting enzyme in arginine synthesis. The arginine-lowering agent PEGylated arginine deiminase (ADI-PEG 20) has shown efficacy as a monot...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-621

    authors: McAlpine JA,Lu HT,Wu KC,Knowles SK,Thomson JA

    更新日期:2014-08-28 00:00:00

  • A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.

    abstract:BACKGROUND:Breast cancer is the most common female cancer worldwide. The lifetime risk of a woman being diagnosed with breast cancer is approximately 12.5%. For women who carry the deleterious mutation in either of the BRCA genes, BRCA1 or BRCA2, the risk of developing breast or ovarian cancer is significantly increase...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-13-138

    authors: Guinan EM,Hussey J,McGarrigle SA,Healy LA,O'Sullivan JN,Bennett K,Connolly EM

    更新日期:2013-03-21 00:00:00

  • Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.

    abstract:BACKGROUND:Many studies have combined sorafenib with transcatheter arterial chemoembolization (TACE) to treat patients with advanced hepatocellular carcinoma (HCC), but the results are disputable. Thus, we conducted this meta-analysis to assess the efficacy and safety of the combination treatment in patients with advan...

    journal_title:BMC cancer

    pub_type: 杂志文章,meta分析

    doi:10.1186/s12885-017-3707-5

    authors: Cai R,Song R,Pang P,Yan Y,Liao Y,Zhou C,Wang S,Zhou X,Wang H,Zhang H,Sun H,Ma H

    更新日期:2017-11-06 00:00:00

  • Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.

    abstract:BACKGROUND:Improved insight into the molecular characteristics of the different ovarian cancer subgroups is needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a) identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovar...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-80

    authors: Vilming Elgaaen B,Olstad OK,Haug KB,Brusletto B,Sandvik L,Staff AC,Gautvik KM,Davidson B

    更新日期:2014-02-11 00:00:00

  • Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) - a study protocol.

    abstract:BACKGROUND:Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world's population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glucose lowering drug cl...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章

    doi:10.1186/s12885-017-3433-z

    authors: Schrijnders D,de Bock GH,Houweling ST,van Hateren KJJ,Groenier KH,Johnson JA,Bilo HJG,Kleefstra N,Landman GWD

    更新日期:2017-06-23 00:00:00

  • A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.

    abstract:BACKGROUND:The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Pro...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2431-x

    authors: Udeh EI,Ofoha CG,Adewole DA,Nnabugwu II

    更新日期:2016-07-07 00:00:00

  • Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.

    abstract:BACKGROUND:Cancer cell resistance to therapeutics can result from acquired or de novo-mediated factors. Here, we have utilised advanced breast cancer cell culture models to elucidate de novo doxorubicin resistance mechanisms. METHODS:The response of breast cancer cell lines (MCF-7 and MDA-MB-231) to doxorubicin was ex...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3953-6

    authors: Lovitt CJ,Shelper TB,Avery VM

    更新日期:2018-01-06 00:00:00

  • Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies.

    abstract:BACKGROUND:Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation with the aim to improve CTC detection with low target antigen...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-206

    authors: Weissenstein U,Schumann A,Reif M,Link S,Toffol-Schmidt UD,Heusser P

    更新日期:2012-05-30 00:00:00

  • Transforming growth factor-β suppresses metastasis in a subset of human colon carcinoma cells.

    abstract:BACKGROUND:TGFβ signaling has typically been associated with suppression of tumor initiation while the role it plays in metastasis is generally associated with progression of malignancy. However, we present evidence here for an anti-metastatic role of TGFβ signaling. METHODS:To test the importance of TGFβ signaling to...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-221

    authors: Simms NA,Rajput A,Sharratt EA,Ongchin M,Teggart CA,Wang J,Brattain MG

    更新日期:2012-06-06 00:00:00

  • Impact of organised programs on colorectal cancer screening.

    abstract:PURPOSE:Colorectal cancer (CRC) screening has been shown to decrease CRC mortality. Organised mass screening programs are being implemented in France. Its perception in the general population and by general practitioners is not well known. METHODS:Two nationwide observational telephone surveys were conducted in early ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-8-104

    authors: Eisinger F,Cals L,Calazel-Benque A,Blay JY,Coscas Y,Dolbeault S,Namer M,Pivot X,Rixe O,Serin D,Roussel C,Morère JF,EDIFICE committee.

    更新日期:2008-04-15 00:00:00

  • COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer.

    abstract:BACKGROUND:ETS variant 1 (ETV1) and E3 ubiquitin ligase constitutive photomorphogenetic 1 (COP1) have been proposed to be a pair of oncogene and tumor suppressor. However, the co-existing status of ETV1 and COP1 in triple-negative breast cancer (TNBC) and their predictive role in determining the patient's outcome are u...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-1151-y

    authors: Ouyang M,Wang H,Ma J,Lü W,Li J,Yao C,Chang G,Bi J,Wang S,Wang W

    更新日期:2015-03-15 00:00:00

  • A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.

    abstract:BACKGROUND:Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve long-term outcome after transplantation. We wanted to prospectively assess feasibility of systemic ant...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章

    doi:10.1186/s12885-019-5760-8

    authors: Eilard MS,Andersson M,Naredi P,Geronymakis C,Lindnér P,Cahlin C,Bennet W,Rizell M

    更新日期:2019-06-11 00:00:00

  • Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients.

    abstract:BACKGROUND:Small cell cervical carcinoma (SCCC) is a rare, aggressive tumor with a poor prognosis. However, information in relation to its treatment is scarce due to the limited numbers of patients. The aim of this study was to establish whether platinum-based combination chemotherapy may by beneficial in this patient ...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1186/1471-2407-14-140

    authors: Huang L,Liao LM,Liu AW,Wu JB,Cheng XL,Lin JX,Zheng M

    更新日期:2014-02-27 00:00:00

  • Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).

    abstract:BACKGROUND:Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of recurrent glioblastoma, too. In both cases, adjuvant treatment, mostly using temozolomide, can improve...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-017-3928-7

    authors: Straube C,Scherb H,Gempt J,Kirschke J,Zimmer C,Schmidt-Graf F,Meyer B,Combs SE

    更新日期:2018-01-03 00:00:00

  • The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.

    abstract:BACKGROUND:Limited studies examine the immune landscape in Esophageal Adenocarcinoma (EAC). We aim to identify novel associations, which may inform immunotherapy treatment stratification. METHODS:Three hundred twenty-nine EAC cases were available in Tissue Microarrays (TMA) format. A discovery cohort of 166 EAC cases ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-06987-y

    authors: Humphries MP,Craig SG,Kacprzyk R,Fisher NC,Bingham V,McQuaid S,Murray GI,McManus D,Turkington RC,James J,Salto-Tellez M

    更新日期:2020-06-01 00:00:00

  • Evaluation of the walk-through inflatable colon as a colorectal cancer education tool: results from a pre and post research design.

    abstract:BACKGROUND:Colorectal cancer (CRC) is a disease that can be prevented through early detection. Through the use of effective educational tools, individuals can become better informed about CRC and understand the importance of screening and early detection. The walk through Inflatable Colon is an innovative educational r...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-626

    authors: Sanchez JI,Palacios R,Cole A,O'Connell MA

    更新日期:2014-08-28 00:00:00

  • Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial.

    abstract:BACKGROUND:Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients' quality of life and cause non-adherence. The recently demonstrated effect of individual expectations on ...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1186/1471-2407-13-426

    authors: von Blanckenburg P,Schuricht F,Albert US,Rief W,Nestoriuc Y

    更新日期:2013-09-18 00:00:00

  • Predictive values of upper gastrointestinal cancer alarm symptoms in the general population: a nationwide cohort study.

    abstract:BACKGROUND:Survival rates for upper gastrointestinal (GI) cancer are poor since many are diagnosed at advanced stages. Fast track endoscopy has been introduced to prompt diagnosis for patients with alarm symptoms that could be indicative of upper GI cancer. However, these symptoms may represent benign conditions and li...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4376-8

    authors: Rasmussen S,Haastrup PF,Balasubramaniam K,Christensen RD,Søndergaard J,Jarbøl DE

    更新日期:2018-04-18 00:00:00

  • Identification of microRNAs and their Endonucleolytic Cleavaged target mRNAs in colorectal cancer.

    abstract:BACKGROUND:Colorectal cancer (CRC) ranks the third among the most common malignancies globally. It is well known that microRNAs (miRNAs) play vital roles in destabilizing mRNAs and repressing their translations in this disease. However, the mechanism of miRNA-induced mRNA cleavage remains to be investigated. METHOD:In...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-06717-4

    authors: Zhou F,Tang D,Xu Y,He H,Wu Y,Lin L,Dong J,Tan W,Dai Y

    更新日期:2020-03-23 00:00:00

  • Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer.

    abstract:BACKGROUND:Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. The purpose of this study was to investigate whether single nu...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-8-382

    authors: Sáenz-López P,Carretero R,Cózar JM,Romero JM,Canton J,Vilchez JR,Tallada M,Garrido F,Ruiz-Cabello F

    更新日期:2008-12-19 00:00:00